Sika

Last updated February 10, 2026

Innovation Areas

3,042

Inventors

Collaborations

Polycyclic scaffold molecular derivatives: SikaRecent Research Landscape

Off-target metabolic effects and poor binding affinity in thyroid hormone pathways lead to systemic toxicity, which is mitigated through precise stereochemical control of polycyclic scaffolds. Engineering these specific chiral arylpropionic structures ensures selective receptor activation while reducing adverse side effects.

What technical problems is Sika addressing in Polycyclic scaffold molecular derivatives?

Viral replication and inflammation

(10)evidences

Chemical scaffolds often lack the necessary binding affinity or biological activity required for effective disease treatment. Increasing potency reduces required dosage and improves clinical outcomes.

Inadequate ligand binding selectivity

(3)evidences

Suboptimal molecular interaction with thyroid and parathyroid hormone receptors. Improving binding strength ensures effective therapeutic modulation at lower dosages.